Quantitative MR Biomarkers for Sarcoma Treatment

This study has been completed.

Sponsor:

Collaborator:

National Institutes of Health (NIH)

Information provided by (Responsible Party):

Gary Luker M.D., University of Michigan

ClinicalTrials.gov Identifier:

NCT01017978

First received: November 20, 2009

Last updated: December 2, 2015

Last verified: December 2015

History of Changes

Purpose

To determine if MRI imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used.

Condition	Intervention
Soft Tissue Tumors	Procedure: MRI Scan of soft tissue tumor


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: None (Open Label)
Official Title:	Quantitative MR Biomarkers for Sarcoma Treatment

Resource links provided by NLM:

MedlinePlus related topics: MRI Scans Nuclear Scans Soft Tissue Sarcoma

Genetic and Rare Diseases Information Center resources: Soft Tissue Sarcoma

U.S. FDA Resources

Further study details as provided by Gary Luker M.D., University of Michigan:

Primary Outcome Measures:

To determine if MRI imaging can accurately determine if a sarcoma (tumor)is responding to the type of chemotherapy being used. [ Time Frame: Baseline prior to chemo ]
To image and evaluate the size of the soft tissue tumor prior to chemotherapy treatment.

Secondary Outcome Measures:

MRI Scan [ Time Frame: 3 weeks post start of chemo and end of chemo ]
To evaluate the size of the soft tissue tumor after start of chemotherapy to determine if the chemo is having any notable effect on tumor prior to surgery.


Enrollment:	11
Study Start Date:	July 2009
Study Completion Date:	April 2012
Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
MRI Scan MRI scan of soft tissue tumor	Procedure: MRI Scan of soft tissue tumor MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.

Detailed Description:

The purpose of this study is to determine if MRI imaging can be used to accurately determine if a sarcoma is responding to the type of chemotherapy being used or if it is ineffective early on in the treatment; instead of finding this out 2-3 months later. If it is determined that MRI can accurately diagnose tumor response, medications can be switched early on potentially improv8ing the patients'chances of recovery.

Eligibility


Ages Eligible for Study:	3 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Biopsy proven primary bone or soft tissue tumor
No previous treatment for this malignancy
Will be given chemotherapy before having surgery or radiation on the tumor.
Are able to undergo a MRI examination
If your tumor measures at least 1/2 inch in length.

Exclusion Criteria:

Younger than 3 yrs. of age or need general anesthesia(sedation that puts you to sleep) to have a MRI performed.
History of Renal Failure
Are not able to have a MRI performed for any reason such as you have a pacemaker or other implanted device that may malfunction or move because of the magnetic field inside the MRI room and scanner.
Have any history of an allergic reaction to gadolinium based contrast agents (a medication injected in a vein that helps create clearer MRI images.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01017978

Locations


United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109

Sponsors and Collaborators

University of Michigan

National Institutes of Health (NIH)

Investigators


Principal Investigator:	Gary Luker, M.D.	Universityof Michigan Health Systems

More Information


Responsible Party:	Gary Luker M.D., Principal Investigator, University of Michigan
ClinicalTrials.gov Identifier:	NCT01017978 History of Changes
Other Study ID Numbers:	HUM 00023415
Study First Received:	November 20, 2009
Last Updated:	December 2, 2015

Additional relevant MeSH terms:


Sarcoma Soft Tissue Neoplasms Neoplasms, Connective and Soft Tissue	Neoplasms by Histologic Type Neoplasms Neoplasms by Site

ClinicalTrials.gov processed this record on August 21, 2017

To Top